Uppsala, Sweden, May 11, 2020. Biovica, active in cancer diagnostics, hosts today its virtual capital market day at 14.00-16.00. The purpose is to provide an update on Biovica's market launch strategy and goals. Biovica is also providing a market share target three years after launch of DiviTum®.
Biovica is approaching market launch of DiviTum® for monitoring of metastatic breast cancer treatments. DiviTum® is already being sold for research purposes, primarily to major pharmaceutical companies for use in clinical studies. After an FDA approval, the large market for patient monitoring will become available.
Three years after market launch, Biovica expects to achieve a market share of 15 percent of the total market potential. The first market will be the United States, followed by Europe's five largest markets and the Nordic region. Thereafter, additional geographic expansion, is planned with initial focus on the Japanese market. Long term is Biovica’s goal to take 50 percent of the market share on the markets we launch DiviTum®.
During the Capital Market Day, CEO Anders Rylander, together with members of Biovica's Group Management, will present the company's strategy and plans. In addition, oncologist MD Samuel Rotstein from Karolinska Hospital will present his views on the value DiviTum® could bring patients and the healthcare system. Robert Dann, SVP Marketing and US Business will present the plan for the market launch of DiviTum® in the US, and Henrik Winther SVP Business Development will present the plan for the market launch of DiviTum® in Europe BIG 5 and Nordics, and the plan for companion diagnostics.
“We are on schedule regarding our 510 (k) application to the FDA. As previously announced, we intend to submit it in the third quarter of 2020.” said Anders Rylander, CEO of Biovica.
Link to Capital Markets Day: www.biovica.com/biovica/investor-relations/events/ questions can be sent to email@example.com.